LGND
Ligand Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: LGND
- PEG Ratio
As of Jun 23, 2026, LGND's PEG ratio of 0.17 reflects its valuation relative to its growth. This value reflects a P/E ratio of 35.37 measured against EPS growth of 209.7%.
LGND PEG ratio history
Ligand Pharmaceuticals's ten years historical PEG ratio has a mean of 0.17. LGND's current PEG ratio of 0.17 aligns with its historical average. LGND reached its maximum PEG ratio of 1.5 during the Sep 2017 quarter over the past ten years. The Mar 2019 quarter had the bottom reading at 0, indicating the most optimal growth-adjusted valuation.
Ligand Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.01 | 29.36 | 3,027.3% |
| 2024 | N/A | N/A | -107.3% |
| 2023 | 0.09 | 23.65 | 252.5% |
| 2022 | N/A | N/A | -157.6% |
| 2021 | 0.02 | 44.9 | 2,011.1% |
| 2020 | N/A | N/A | -100.5% |
| 2019 | 0.01 | 3.15 | 389.4% |
| 2018 | 0.02 | 20.04 | 1,028.3% |
| 2017 | 0.27 | 228.22 | 850% |
| 2016 | N/A | N/A | -100.7% |
| 2015 | 0.01 | 9.34 | 1,867.8% |
| 2014 | 16.7 | 90.19 | 5.4% |
| 2013 | 0.05 | 93.93 | 1,966.7% |
| 2012 | N/A | N/A | -106.1% |
| 2011 | 0.13 | 24.22 | 192.5% |
Ligand Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.12 | 25.27 | 209.7% |
| Dec 2025 | 0.01 | 29.36 | 3,027.3% |
| Sep 2025 | N/A | 76.68 | -12.5% |
| Jun 2025 | N/A | N/A | -266.8% |
| Mar 2025 | N/A | N/A | -232.1% |
| Dec 2024 | N/A | N/A | -107.3% |
| Sep 2024 | 0.22 | 37.91 | 175% |
| Jun 2024 | 0.62 | 34.53 | 55.4% |
| Mar 2024 | 0.05 | 13.41 | 292.1% |
| Dec 2023 | 0.09 | 23.65 | 252.5% |
| Sep 2023 | 0.36 | 62.42 | 175.6% |
| Jun 2023 | 0.11 | 45.92 | 434% |
| Mar 2023 | N/A | 52.92 | -2.1% |
| Dec 2022 | N/A | N/A | -157.6% |
| Sep 2022 | N/A | N/A | -130.8% |
LGND average PEG ratio chart
LGND's PEG ratio today sits above its 5-year average, yet it is lower than the 3-year average.
PEG comparison
With a PEG of 0.17, LGND stands below the Healthcare sector and the industry average. Looking at its Healthcare sector average of 0.56, Ligand Pharmaceuticals's PEG is 70% lower.
LGND EPS growth
LGND Price vs fair value
LGND PEG vs peers
LGND has a PEG ratio below that of peer stocks LLY and AMGN.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| LGND Ligand Pharmaceuticals Inc | 0.17 | $5.6B |
| LLY ELI LILLY & Co | 0.31 | $1.04T |
| BMY Bristol Myers Squibb Co | 0.47 | $113.4B |
| AMGN Amgen Inc | 0.77 | $187.28B |
| MRK Merck & Co Inc | N/A | $295.39B |
| PFE Pfizer Inc | N/A | $140.89B |
| JNJ Johnson & Johnson | N/A | $575.52B |
| BAX Baxter International Inc | N/A | $10.38B |
Frequently asked questions
What is Ligand Pharmaceuticals's PEG ratio?
LGND's Jun 23, 2026 PEG ratio comes in at 0.17.
What is the 3-year average PEG ratio for Ligand Pharmaceuticals (LGND)?
LGND has a 3-year average PEG ratio of 0.2.
What is the 5-year average PEG ratio for Ligand Pharmaceuticals (LGND)?
LGND has a 5-year average PEG ratio of 0.15.
What is the highest PEG ratio for LGND?
In the last ten years, LGND's peak PEG ratio of 1.5 was recorded in the Sep 2017 quarter.
How does the current PEG ratio for LGND compare to its historical average?
LGND's PEG ratio equals its 10-year historical average.
Why is Ligand Pharmaceuticals's PEG ratio so low?
The 0.17 PEG ratio for LGND reflects strong earnings growth outpacing the current valuation.
How is LGND's PEG ratio calculated (Ligand Pharmaceuticals PEG ratio formula)?
The PEG ratio comes from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jun 23, 2026, Ligand Pharmaceuticals has a P/E ratio of 35.37. Earnings grew at 209.7% over the TTM period ending Mar 2026. Applying the formula, this gives a price to earnings growth ratio of 0.17. PEG RATIO(0.17) = PE RATIO(35.37) / EPS GROWTH(209.7%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.